clinvestКачественная клиническая практикаKachestvennaya Klinicheskaya Praktika = Good Clinical Practice2588-05192618-8473ООО «Издательство ОКИclinvest-481Research ArticleОЦЕНКА ТЕХНОЛОГИЙ ЗДРАВООХРАНЕНИЯHEALTH TECHNOLOGY ASSESSMENTЭкономические аспекты C. difficile-ассоциированной диареи: взгляд с позиций госпитальной оценки технологий здравоохраненияClostridium difficile associated infection: view of hospital-based health technology assessmenthttps://orcid.org/0000-0001-7704-9900ГомонЮ. М.GomonY. M.

Гомон Юлия Михайловна - к. м. н., врач-клинический фармаколог СПб ГБУЗ «Городская больница Святого Великомученика Георгия», доцент кафедры клинической фармакологии и доказательной медицины, ПСПбГМУ им. акад. И.П. Павлова

Санкт-Петербург

Gomon Yulia - Candidate of Medical Sciences, physician-clinical pharmacologist, St. George the Martyr city hospital, St. Petersburg; Associate Professor at the Department of clinical pharmacology and evidence-based medicine, FSBEI HE I.P. Pavlov SPbSMU MOH Russia

Saint-Petersburg

gomonmd@yandex.ruФГБОУ ВО «Первый Санкт-Петербургский государственный медицинский университет им. академика И.П. Павлова»; СПб ГБУЗ «Городская больница Святого Великомученика Георгия»РоссияFSBEI HE I.P. Pavlov SPbSMU MOH Russia; St. George the Martyr city hospitalRussian Federation201908042020043339Copyright © Гомон Ю.М., 20202020Гомон Ю.М.Gomon Y.M.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.clinvest.ru/jour/article/view/481Clostridium-difficile-ассоциированный колитоценка технологий здравоохраненияэкономические исходыClostridium difficile associated infectionhealth technology assessmenteconomic outcomeReferencesКлинические рекомендации по диагностике Clostridium difficile-ассоциированной диареи (Электронный документ). — Режим доступа: http://www.gnck.ru/rec/recommendation_clostridium_difficile.pdfKlinicheskiye recommendacii po diagnostike Clostridium difficile-associirovannoi diarei. — Access: http://www.gnck.ru/rec/recommendation_clostridium_difficile.pdf (In Russ.)Clinical Practice Guidelines for Clostridium difficile Infection in Adults and Children: 2017 Update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA) (Электронный документ). — Режим доступа: https://www.idsociety.org/practiceguideline/clostridium-difficile/Clinical Practice Guidelines for Clostridium difficile Infection in Adults and Children: 2017 Update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA) (Электронный документ). — Режим доступа: https://www.idsociety.org/practiceguideline/clostridium-difficile/Lessa FC, Mu Y, Bamberg WM, et al. Burden of Clostridium difficile infection in the United States. N Engl J Med. 2015;372:825-834.Lessa FC, Mu Y, Bamberg WM, et al. Burden of Clostridium difficile infection in the United States. N Engl J Med. 2015;372:825-834.Dubberke ER, Olsen MA. Burden of Clostridium difficile on the healthcare system. Clin Infect Dis. 2012;55 (Suppl 2):S88-S92.Dubberke ER, Olsen MA. Burden of Clostridium difficile on the healthcare system. Clin Infect Dis. 2012;55 (Suppl 2):S88-S92.Stranges PM, Hutton DW, Collins CD. Cost-effectiveness analysis evaluating fidaxomicin versus oral vancomycin for the treatment of Clostridium difficile infection in the United States. Value Health. 2013;16(2):297-304. DOI:10.1016/j.jval.2012.11.004Stranges PM, Hutton DW, Collins CD. Cost-effectiveness analysis evaluating fidaxomicin versus oral vancomycin for the treatment of Clostridium difficile infection in the United States. Value Health. 2013;16(2):297-304. DOI:10.1016/j.jval.2012.11.004Bouza E. Consequences of Clostridium difficile infection: understanding the healthcare burden. Clin Microbiol Infect. 2012 Dec;18 Suppl 6:5-12. DOI: 10.1111/1469-0691.12064Bouza E. Consequences of Clostridium difficile infection: understanding the healthcare burden. Clin Microbiol Infect. 2012 Dec;18 Suppl 6:5-12. DOI: 10.1111/1469-0691.12064Heimann SM, Cruz Aguilar MR, Mellinghof S, Vehreschild MJGT. Economic burden and cost-effective management of Clostridium difficile infections. Med Mal Infect. 2018;48(1):23-29. DOI: 10.1016/j.medmal.2017.10.010Heimann SM, Cruz Aguilar MR, Mellinghof S, Vehreschild MJGT. Economic burden and cost-effective management of Clostridium difficile infections. Med Mal Infect. 2018;48(1):23-29. DOI: 10.1016/j.medmal.2017.10.010Magee G, Strauss ME, Thomas SM, et al. Impact of Clostridium difficileassociated diarrhea on acute care length of stay, hospital costs, and readmission: A multicenter retrospective study of inpatients, 2009-2011. Am J Infect Control. 2015;43(11):1148-53. DOI: 10.1016/j.ajic.2015.06.004Magee G, Strauss ME, Thomas SM, et al. Impact of Clostridium difficileassociated diarrhea on acute care length of stay, hospital costs, and readmission: A multicenter retrospective study of inpatients, 2009-2011. Am J Infect Control. 2015;43(11):1148-53. DOI: 10.1016/j.ajic.2015.06.004Blossom DB, McDonald LC. The challenges posed by reemerging Clostridium difficile infection. Clin Infect Dis. 2007;45:222-227.Blossom DB, McDonald LC. The challenges posed by reemerging Clostridium difficile infection. Clin Infect Dis. 2007;45:222-227.Brown KA, Khanafer N, Daneman N, Fisman DN. Meta-analysis of antibiotics and the risk of community-associated Clostridium difficile infection. Antimicrob Agents Chemother. 2013 May;57(5):2326-32. DOI: 10.1128/AAC.02176-12Brown KA, Khanafer N, Daneman N, Fisman DN. Meta-analysis of antibiotics and the risk of community-associated Clostridium difficile infection. Antimicrob Agents Chemother. 2013 May;57(5):2326-32. DOI: 10.1128/AAC.02176-12Гомон Ю.М., Курылев А.А., Колбин А.С. Анализ потребления антибактериальных препаратов для системного применения в стационарах г. Санкт-Петербурга в 2014—2015 гг. // Журнал инфектологии. — 2018. — Т.10. —№3. — С.115-123. DOI: 10.22625/2072-6732-2018-10-3-115-123Gomon YuM, Kurylev AA, Kolbin AS. Analysis of consumption of antibacterial drugs for systemic use in hospitals of Saint Petersburg in 2014-2015. Journal Infectology. 2018;10(3):115-123. (In Russ). DOI: 10.22625/2072-6732-2018-10-3-115-123Гомон Ю.М., Колбин А.С., Светличная Ю.С., и др. Комплексная оценка потребления антимикробных препаратов в госпитальном сегменте Санкт-Петербурга в 2014—2018 гг. // Клиническая микробиология и антимикробная химиотерапия. — 2019. — Т.21. —№3. — С.238-244. DOI: 10.36488/cmac.2019.3.238-244Gomon YuM, Kolbin AS, Svetlichnaya YuS. Integrated analysis of antibiotic consumption in the hospital segment of Saint-Petersburg in 2014—2018. CMAC 2019;21(3):238-244. (In Russ). DOI: 10.36488/cmac.2019.3.238-244WHO report on surveillance of antibiotic consumption: 2016-2018 early implementation [Электронный ресурс]. — Geneva: World Health Organization; 2018. — Режим доступа: http://www.who.int/medicines/areas/rational_use/who-amr-amc-report-20181109.pdf?ua=1WHO report on surveillance of antibiotic consumption: 2016-2018 early implementation [Электронный ресурс]. — Geneva: World Health Organization; 2018. — Режим доступа: http://www.who.int/medicines/areas/rational_use/who-amr-amc-report-20181109.pdf?ua=1McDonald LC, Gerding DN, Johnson S, et al. Clinical practice guidelines for Clostridium difficile infection in adults and children: 2017 update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA). Clin Infect Dis. 2018;66:e1-e48.McDonald LC, Gerding DN, Johnson S, et al. Clinical practice guidelines for Clostridium difficile infection in adults and children: 2017 update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA). Clin Infect Dis. 2018;66:e1-e48.Гомон Ю.М., Колбин А.С., Сидоренкo С.В., и др. Клинико-экономическая оценка эффективности и безопасности существующей практики проведения периоперационной антибиотикопрофилактики на оcнове фармакоэпидемиологического исследования в многопрофильных стационарах Санкт-Петербурга // ФАРМАКОЭКОНОМИКА. Современная фармакоэкономика и фармакоэпидемиология. — 2017. — Т.10. —№2. С.3-11. DOI: 10.17749/20704909.2017.10.2.003-011Gomon YuM, Kolbin AS, Sidorenko SV, et al. Economic assessment of the effectiveness and safety of the commonly practiced perioperative antibiotic prophylaxis: (based on an earlier epidemiological survey of multidisciplinary hospitals). PHARMACOECONOMICS. Modern pharmacoeconomics and pharmacoepidemiology. 2017;10(2):3-11. (In Russ). DOI: 10.17749/20704909.2017.10.2.003-011Гомон ЮМ. Периоперационная профилактика в хирургии: анализ влияния на бюджет // Вестник Санкт-Петербургского университета. Медицина. — 2018. — Т13. —№3. — С.301-315. DOI:10.21638/11701/Spbu11.2018.307Gomon YuM. Perioperative antibiotic prophylaxis: Budget impact analysis. Vestnik of Saint-Petersburg University. Medicine. (In Russ). DOI:10.21638/11701/Spbu11.2018.307Song X, Bartlett JG, Speck K, et al. Rising economic impact of Clostridium difficile-associated disease in adult hospitalized patient population. Infect Control Hosp Epidemiol. 2008;29:823-828.Song X, Bartlett JG, Speck K, et al. Rising economic impact of Clostridium difficile-associated disease in adult hospitalized patient population. Infect Control Hosp Epidemiol. 2008;29:823-828.Kyne L, Hamel MB, Polavaram R, Kelly CP. Health care costs and mortality associated with nosocomial diarrhea due to Clostridium difficile. Clin Infect Dis. 2002;34:346-353.Kyne L, Hamel MB, Polavaram R, Kelly CP. Health care costs and mortality associated with nosocomial diarrhea due to Clostridium difficile. Clin Infect Dis. 2002;34:346-353.

The authors declare that there are no conflicts of interest present.